Singapore, July 17, 2025 — Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced it has placed a hold on its planned acquisition of a BTC digital asset. Following comprehensive discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually decided to defer the digital asset purchase. This choice reflects the ongoing regulatory scrutiny of digital assets by US authorities and the current lack of clarity regarding how forthcoming policies might affect the transaction.

In light of these uncertainties, both parties believe it is a prudent step to postpone the deal until greater regulatory certainty emerges. We intend to closely monitor developments and re-evaluate the opportunity once the regulatory landscape becomes clearer.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider specializing in orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, and neurosurgical treatments. Its operations are centered in Singapore, with clinics located at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre. Over the past two decades, the group has cultivated robust and enduring relationships with a broad base of corporations, particularly within the construction, marine, and oil & gas industries, which underpin its resilient business model. As an orthopedic service provider in Singapore with a track record spanning over 20 years, Basel Medical is strategically positioned to capitalize on the growth opportunities within Singapore’s private healthcare sector and across Southeast Asia. These opportunities are driven by factors such as aging populations, rising income levels, increasing private insurance coverage, governmental healthcare initiatives and expenditure, growing sports participation rates, and Singapore’s status as a premier destination for healthcare services in Asia. Its management and medical practitioner team comprises a roster of specialists in orthopedics and neurosurgery, along with experts in corporate finance and healthcare partnerships. Basel Medical Group Ltd serves as the holding company for its group, conducting operations through its Singapore-based operating subsidiaries. For more information, please visit the Company’s website: .

Forward-Looking Statements

This announcement contains certain forward-looking statements, which inherently involve known and unknown risks and uncertainties. These statements are based on the Company’s current expectations and projections regarding future events that may influence its financial condition, operational results, business strategy, and financial requirements. Investors can identify many (though not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions within this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events, changing circumstances, or shifts in its expectations, except as may be legally required. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will prove correct. The Company cautions investors that actual results may differ materially from anticipated outcomes and encourages investors to review other factors that could affect its future results, as detailed in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd
+65 6291 9188